Press Releases

Date Title
Toggle Summary Kura Oncology to Report Third Quarter 2019 Financial Results
SAN DIEGO , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close of
Toggle Summary Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – – 8 efficacy-evaluable patients enrolled since last update include 3 confirmed PRs, 2 unconfirmed PRs
Toggle Summary Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29 th – – Previously announced poster presentation rescheduled to take place following oral presentation – – Data embargoed until 11:50 a.m.
Toggle Summary Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical trial of tipifarnib
Toggle Summary Kura Oncology Expands Board of Directors with Appointment of Diane Parks
– Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness – SAN DIEGO , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision
Toggle Summary Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company
Toggle Summary Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma
– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – – Proof-of-concept trial sponsored by Samsung Medical Center in Seoul, Korea – –
Toggle Summary Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is
Toggle Summary Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
Appointment enhances leadership team with focus on strategic planning and operational execution SAN DIEGO , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,
Toggle Summary Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,